Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Cordes

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2019
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory MoleculesMargaret E Gatti-Mays, Julius Strauss, Renee N Donahue, et al.
European Urology Oncology|October 20, 2023
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with EnzalutamideShruti U Gandhy, Fatima H Karzai, Marijo Bilusic, et al.
The Oncologist|October 10, 2019
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced CancerMargaret E Gatti-Mays, Jason M Redman, Renee N Donahue, et al.
The Oncologist|March 11, 2022
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal CancerJason M Redman, Yo-Ting Tsai, Benjamin A Weinberg, et al.
JAMA Oncology|February 20, 2025
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical TrialCharalampos S Floudas, Meghali Goswami, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerHoussein Abdul Sater, Jennifer L Marté, Renee N Donahue, et al.
Cancer Immunology, Immunotherapy : CII|March 21, 2025
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancerCharalampos S Floudas, Meghali Goswami, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|December 16, 2020
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignanciesJulius Strauss, Margaret E Gatti-Mays, Byoung Chul Cho, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2019
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory MoleculesMargaret E Gatti-Mays, Julius Strauss, Renee N Donahue, et al.
European Urology Oncology|October 20, 2023
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with EnzalutamideShruti U Gandhy, Fatima H Karzai, Marijo Bilusic, et al.
The Oncologist|October 10, 2019
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced CancerMargaret E Gatti-Mays, Jason M Redman, Renee N Donahue, et al.
The Oncologist|March 11, 2022
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal CancerJason M Redman, Yo-Ting Tsai, Benjamin A Weinberg, et al.
JAMA Oncology|February 20, 2025
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers: A Nonrandomized Clinical TrialCharalampos S Floudas, Meghali Goswami, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerHoussein Abdul Sater, Jennifer L Marté, Renee N Donahue, et al.
Cancer Immunology, Immunotherapy : CII|March 21, 2025
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancerCharalampos S Floudas, Meghali Goswami, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|December 16, 2020
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignanciesJulius Strauss, Margaret E Gatti-Mays, Byoung Chul Cho, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
Pageof 4